Holy Cross Hospital Now Offering Pipeline® Embolization Device for Treatment of Aneurysms
New device offers hope for patients who previously had no other treatment option
Holy Cross Hospital announced it is now offering the newly FDA-approved Pipeline® Embolization Device for patients who previously had limited treatment options if suffering from a certain type of aneurysm, an abnormal, blood-filled ballooning in the wall of a blood vessel. It is estimated that one in 15 people in the U.S. will develop a brain aneurysm during their lifetime.
“The Pipeline Embolization Device may offer improved patient results with a safe and effective treatment of large or giant, wide-necked aneurysms, which until now has been an unmet clinical need,” said Laszlo Miskolczi, MD, an internationally acclaimed, board-certified neurointerventional radiologist at Holy Cross.
To reduce the likelihood of rupturing, the Pipeline Embolization Device is placed across the opening (or "neck") of a large or giant, wide-necked brain aneurysm of the internal carotid artery. The device diverts blood flow away from the aneurysm and causes the blood that remains in the aneurysm to safely clot and form an unpenetrable barrier. This prevents the rupture of the aneurysm, causes the aneurysm to shrink in size over time and later possibly even disappear.
The Pipeline Embolization Device, considered a less invasive treatment compared to an open surgical procedure, is intended to treat adults 22 years of age and older.
“The significance of having a device that can divert blood flow away from an aneurysm may change how aneurysms are treated,” Dr. Miskolczi said.
Neurointerventional Radiology at Holy Cross Hospital
In addition to the Pipeline Embolization Device, Holy Cross Hospital’s state-of-the-art equipment offers new X-ray technologies that increase the traditional time frame during which effective stroke treatment can be delivered. Patients at Holy Cross Hospital now may recover completely even from severe stroke if they arrive within eight hours after the onset of symptoms. Dr. Miskolczi is one of the first physicians in the United States to study and teach stroke treatment using this new technology.
Dr. Miskolczi also is a pioneer in Solitaire thrombectomy, a new procedure that clears arterial blockages in the brain after traditional stroke treatments fail.
Under his leadership, Holy Cross Hospital has been recognized by the American Heart Association and American Stroke Association through the organizations' Get With The Guidelines®-Stroke (GWTG-Stroke) program with the Gold Plus Award, the highest recognition possible. The Gold Plus Award is an advanced level of recognition that allows hospitals to be acknowledged for their long-term compliance to the quality measures within the GWTG-Stroke program.